Exscientia And Sanofi Will Search For 15 Novel Oncology, Immunology Drugs Under New Pact
Executive Summary
Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.
You may also be interested in...
The Top Five Biopharma Alliances Of Q1
With the help of Biomedtracker’s Dealmaking Quarterly Statistics report, Scrip takes a look at the five biggest alliances by value in the first quarter and how they could shape the future of the companies involved, from big pharma to biotech.
Seismic Hopes To Shake Up Immunology With New Financing
Financing Snapshot: The AI/ML-focused company raised $101m in a series A round and plans to use the funding to develop immunoglobulin- and cell-mediated autoimmune disorder drugs.
Sanofi Pairs Up With Non-Profit Protas In Quest To Cut Clinical Trial Costs
The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.